CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study

Plain-language summary

This study examined how changes in the CYP2C19 gene relate to resistance to thienopyridine medicines (clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). It was open to patients over 20 with stable effort angina undergoing elective PCI treated with aspirin and clopidogrel. Run by Kumamoto University, it was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Kumamoto University

Start date

12/1/2008

Estimated completion

9/1/2010

Countries

Japan

Related genes

Locations

• Kumamoto, Japan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* The stable effort angina patients
* More than 20 years old
* Undergoing elective PCI treated with aspirin and clopidogrel

Exclusion Criteria:

* Patients treated with the following medical therapy (ie. Warfarin, Steroid, thrombolytic drug, Ticlopidine, Sarpogrelate hydrochloride or Cilostazol)
* Patients with the following diseases (deep vein thrombosis, atrial fibrillation, collagen disease, infection, liver or renal dysfunction, malignant diseases)